|Bid||0.00 x 3100|
|Ask||0.00 x 1000|
|Day's Range||6.47 - 7.15|
|52 Week Range||2.44 - 7.85|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.67|
Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and.
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission Company.
BURLINGTON, Mass., Aug. 06, 2019 -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential.
BURLINGTON, Mass., May 30, 2019 -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to.
“We enter 2019 with good momentum and an increasingly clear line of sight on what we need to accomplish to refile our NDA for FUROSCIX in 2020,” said John Tucker, president and chief executive officer of scPharmaceuticals. “We look forward to working with the FDA in June to solidify refiling requirements. In the interim, we anticipate initiating our first human factors study using our next generation delivery device, the West Pharmaceutical Services, Inc. (West) SmartDose® drug delivery system with FUROSCIX.
The latest earnings release scPharmaceuticals Inc.'s (NASDAQ:SCPH) announced in December 2018 revealed that losses became smaller relative to the prior year's level - great news for investors...
Signed development agreement with West Pharmaceutical Services for next-generation FUROSCIX® On-Body Infusor Resubmission of FURSOCIX with the U.S. Food and Drug Administration.
BURLINGTON, Mass., Feb. 21, 2019 -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential.
Advancing FUROSCIX® with the SmartDose® Drug Delivery System Forecast 2018 year-end cash of $82 - $87 million and 2019 expenditures of $8 - $10 million per quarter BURLINGTON,.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Resubmission of FURSOCIX® with the U.S. Food and Drug Administration (FDA) by year-end 2019 Balance sheet remains strong with over $95 million in cash BURLINGTON, Mass., Nov..